Relationship Between Time-Varying Achieved High-Density Lipoprotein Cholesterol and Risk of Coronary Events Depends on Haptoglobin Phenotype Within the ACCORD Lipid Study

被引:2
作者
Warren, Rachel A. [1 ,2 ]
Carew, Allie S. [1 ,2 ,3 ]
Andreou, Pantelis [3 ]
Levy, Andrew P. [4 ]
Sapp, John [1 ,2 ]
Lache, Orit [4 ]
Ginsberg, Henry N. [5 ]
Rimm, Eric B. [6 ,7 ]
Herman, Christine [2 ,8 ]
Kirkland, Susan [1 ,3 ]
Cahill, Leah E. [1 ,2 ,3 ]
机构
[1] Dalhousie Univ, Dept Med, 5790 Univ Ave, Halifax, NS B3H 1V7, Canada
[2] Nova Scotia Hlth Author, QEII Hlth Sci Ctr, Halifax, NS, Canada
[3] Dalhousie Univ, Dept Community Hlth & Epidemiol, Halifax, NS, Canada
[4] Technion Israel Inst Technol, Rappaport Fac Med, Hefa, Israel
[5] Columbia Univ, Dept Med, New York, NY USA
[6] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA
[7] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA
[8] Dalhousie Univ, Dept Surg, Halifax, NS, Canada
来源
JOURNAL OF THE AMERICAN HEART ASSOCIATION | 2023年 / 12卷 / 19期
关键词
coronary artery disease; epidemiology; genetic association; HDL-cholesterol; type; 2; diabetes; IN-VITRO; GENOTYPE; DISEASE; INDIVIDUALS; HDL; POLYMORPHISM; HEMOGLOBIN; MORTALITY; NIACIN; ASSOCIATION;
D O I
10.1161/JAHA.123.030288
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: The Hp (haptoglobin)2-2 phenotype (similar to 40% of people) is associated with dysfunctional high-density lipoprotein (HDL) that is heavily oxidized in hyperglycemia, which may explain why raising HDL-cholesterol (HDL-C) does not reliably prevent coronary artery disease (CAD) in diabetes. METHODS AND RESULTS: In this observational study using longitudinal data from the ACCORD (Action to Control Cardiovascular Risk in Diabetes) lipid trial, time-varying (achieved) HDL-C updated at 4, 8, and 12 months, and annually thereafter over a mean of 4.7 years, was analyzed in relation to risk of CAD and secondary outcomes using Cox proportional hazards regression with time-varying covariables among participants with (n=1781) and without (n=3191) the Hp2-2 phenotype. HDL-C did not differ between the phenotypes throughout the study. Having low HDL-C (<40 mg/dL for male participants and <50 mg/dL for female participants) was associated with a greater risk of CAD compared with non-low HDL-C among participants with the non-Hp2-2 phenotype (hazard ratio [HR], 1.48 [95% CI, 1.18-1.87]) but not among the Hp2-2 phenotype (HR, 0.97 [95% CI, 0.70-1.35]; P interaction=0.03). Similarly, an inverse relationship was observed between HDL-C quintiles and CAD risk among participants without the Hp2-2 phenotype, whereas no significant inverse relationship was observed among participants with the Hp2-2 phenotype (P interaction=0.38). Among the Hp2-2 phenotype group, having low HDL-C was associated with higher risk of CVD mortality (HR, 2.09 [95% CI, 1.05-4.13]), and compared with the lowest HDL-C quintile, higher quintiles were associated with lower risk of CVD mortality and congestive heart failure. CONCLUSIONS: Hp phenotype modified the association between HDL-C and risk of CAD in the ACCORD lipid study, suggesting that HDL dysfunction in the Hp2-2 phenotype may hinder CAD-protective properties of HDL-C.
引用
收藏
页数:15
相关论文
共 42 条
  • [31] Mody Purav, 2012, Circ Cardiovasc Qual Outcomes, V5, pe33, DOI 10.1161/CIRCOUTCOMES.112.967638
  • [32] Sex differences in lipid and lipoprotein metabolism
    Palmisano, Brian T.
    Zhu, Lin
    Eckel, Robert H.
    Stafford, John M.
    [J]. MOLECULAR METABOLISM, 2018, 15 : 45 - 55
  • [33] Sex Disparities in the Quality of Diabetes Care: Biological and Cultural Factors May Play a Different Role for Different Outcomes A cross-sectional observational study from the AMD Annals initiative
    Rossi, Maria Chiara
    Cristofaro, Maria Rosaria
    Gentile, Sandro
    Lucisano, Giuseppe
    Manicardi, Valeria
    Mulas, Maria Franca
    Napoli, Angela
    Nicolucci, Antonio
    Pellegrini, Fabio
    Suraci, Concetta
    Giorda, Carlo
    [J]. DIABETES CARE, 2013, 36 (10) : 3162 - 3168
  • [34] Dysfunctional HDL: the journey from savior to slayer
    Serban, Corina
    Muntean, Danina
    Mikhailids, Dimitri P.
    Toth, Peter P.
    Banach, Maciej
    [J]. CLINICAL LIPIDOLOGY, 2014, 9 (01) : 49 - 59
  • [35] Women and Ischemic Heart Disease Evolving Knowledge
    Shaw, Leslee J.
    Bugiardini, Raffaelle
    Merz, C. Noel Bairey
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 54 (17) : 1561 - 1575
  • [36] Haptoglobin polymorphism and lacunar stroke
    Staals, Julie
    Pieters, Barbe M. A.
    Knottnerus, Iris L. H.
    Rouhl, Rob P. W.
    van Oostenbrugge, Robert J.
    Delanghe, Joris R.
    Lodder, Jan
    [J]. CURRENT NEUROVASCULAR RESEARCH, 2008, 5 (03) : 153 - 158
  • [37] Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction
    Suleiman, M
    Aronson, D
    Asleh, R
    Kapeliovich, MR
    Roguin, A
    Meisel, SR
    Shochat, M
    Sulieman, A
    Reisner, SA
    Markiewicz, W
    Hammerman, H
    Lotan, R
    Levy, NS
    Levy, AP
    [J]. DIABETES, 2005, 54 (09) : 2802 - 2806
  • [38] High-density lipoproteins: A consensus statement from the National Lipid Association
    Toth, Peter P.
    Barter, Philip J.
    Rosenson, Robert S.
    Boden, William E.
    Chapman, M. John
    Cuchel, Marina
    D'Agostino, Ralph B., Sr.
    Davidson, Michael H.
    Davidson, W. Sean
    Heinecke, Jay W.
    Karas, Richard H.
    Kontush, Anatol
    Krauss, Ronald M.
    Miller, Michael
    Rader, Daniel J.
    [J]. JOURNAL OF CLINICAL LIPIDOLOGY, 2013, 7 (05) : 484 - 525
  • [39] Waldron IR, The impact of inequality on health in Canada: a multi-dimensional framework
  • [40] Haptoglobin Phenotype Modifies the Effect of Fenofibrate on Risk of Coronary Event: ACCORD Lipid Trial
    Warren, Rachel A.
    Carew, Allie S.
    Andreou, Pantelis
    Herman, Christine
    Levy, Andrew P.
    Ginsberg, Henry N.
    Sapp, John
    Rimm, Eric B.
    Kirkland, Susan
    Cahill, Leah E.
    [J]. DIABETES CARE, 2022, 45 (01) : 241 - 250